Albert Einstein College of Medicine

Industrial Research Limited

Victoria Link Limited

Other

The University of Liverpool

Merck + Co., Inc.

Alber Einslein College of Medicine

Callaghan Innovation Research Limited

Albert Einstein College of Medecine of Yeshiva University

Peter Charles Tyler

Vern L Schramm

Richard Hubert Furneaux

Gary Brian Evans

Keith Clinch

Olga Vladimirovna Zubkova

Peter Michael Kelly

Jeremy E Turnbull

Shivali Ashwin Gulab

Jennifer Mary Mason

Dirk Henning Lenz

Alistair Ian Longshaw

Anthony David Woolhouse

Richard Fröhlich

Robert N Young

Gideon A Rodan

Kami Kim

Ben William Greatrex

Quan Du

Douglas Ronald Crump

Antti Marko Haapalainen

Richard Frohlich

Andrew Munkacsi

Shivall Ashwah Ashwin Gulab

Farah Lamiable-Oulaidi

Karl Jürgen Shaffer

Ashna Ashneen Khan

Shanzhi Wang

Ralf Schwoerer

Simon Peter Harold Mee

Richard Hurbert Furneaux

Richard Froehlich

Provided herein are inhibitors of DNA methyltransferase 1 (an enzyme responsible for the maintenance of DNA CpG methylation marks in human cells) and their use for inhibiting DNA methyltransferase 1. The invention relates to compounds, pharmaceutical compositions, and methods for inhibiting DNA methyltransferase 1. The inhibitors are compounds of the general formula: 

Inhibitors of DNMT1 as anticancer therapeutic agents

The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical and cosmeceutical compositions containing the compounds, and methods of treating cancer, inflammation, diabetic nephropathy, neurodegenerative disorders, Niemann-Pick Type C disease, or dermatological conditions.

Heparan sulfate glycomimetic compounds and their pharmaceutical and cosmeceutical uses

Methods of treating infections due to(), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering to the subject an inhibitor ofMTAN (5'-methylthioadenosine nucleosidase) having the structure of formula (I) 

Treatment of helicobacter pylori infections

The invention relates to salt forms of (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-(methyl-thiomethyl)pyrrolidin-3-ol, as well as polymorphic forms of the salts. The invention further relates to processes for preparing the salt forms and to the use of the salt forms in the treatment of diseases and disorders where it is desirable to inhibit 5'-methylthioadenosine phosphorylase (MTAP).

Salt and polymorphic forms of (3R,4S)-L-((4-amino-5H-pyrrolo[3,2,-D]pyrimidin-7-yl)methyl)-4(methylthiomethyl)pyrodin-3-ol(MTDIA)

Salt and polymorphic forms of (3R,4S)-L-((4-amino-5H-pyrrolo[3,2,-d]pyrimidin-7-yl)methyl)-4(methylthiomethyl)pyrodin-3-ol(MTDIA)

The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (1) which are inhibitors of 5'-methylthioadenosine phosphorylase or 5&#x2032;-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5&#x2032;-methylthioadenosine phosphorylase or 5&#x2032;-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.

3-hydroxypyrrolidine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase

The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, processes for preparing the compounds, and methods of treating diseases or conditions in which it is desirable to inhibit &#x3b2;-secretase.

Saccharide dendritic cluster compounds as inhibitors of BACE-1

The invention relates to compounds that are useful for the preparation of dendrimer compounds, the use of these compounds for preparing dendrimers and processes for preparing the compounds.

Dendritic core compounds

Methods and devices are disclosed for treating or preventing infections in a subject due tousing coformycin analogs and inhibitors of5'-methylthioadenosine deaminase (MTADA).

[object Object]

The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (I) which are inhibitors of 5'-methylthioadenosine phosphorylase or 5&#x2032;-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5&#x2032;-methylthioadenosine phosphorylase or 5&#x2032;-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.

The invention relates generally to oligosaccharide compounds and the use of these compounds as pharmaceuticals for treating diseases or conditions in which it is desirable to inhibit &#x3b2;-secretase.

Oligosaccharide compounds

The present invention discloses methods for treating bacterial infections in a subject comprising administering to the subject a sub-growth inhibiting amount of a 5'-methylthioinosine phosphorylase (MTIP) inhibitor, as well as assays for identifying such inhibitors, and compounds and pharmaceutical compositions comprising the inhibitors.

Methods, assays and compounds for treating bacterial infections by inhibiting methylthioinosine phosphorylase

Inhibitors of saporin-L1 are disclosed, as are related compositions and uses thereof, in particular in cancer therapy that employs saporin-L1-linked immunotoxins.

Saporin-L1 inhibitors and uses thereof

The invention relates to compounds of the general formula (I) which are inhibitors of purine nucleoside phosphorylases (PNPs) and/or nucleoside hydrolases (NHs). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and to pharmaceutical compositions containing the compounds.

Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases

This invention relates to compounds that are analogues of coformycin, pharmaceutical compositions containing the compounds, and methods of using the compounds for treating protozoan parasite infections, especially malaria.

Growing community of inventors

Wellington, New Zealand

Peter Charles Tyler